节拍化疗在晚期非小细胞肺癌中的研究进展  

Research Advances of metronomic Chemotherapy in Non-small Cell Lung Cancer

作　　者：于越 刘宝刚[1] Yu Yue;Liu Baogang(Department of Respiratory and Pulmonary Diseases,Harbin Medical University Cancer Hospital,Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院呼吸肺病内科,150000

出　　处：《中国综合临床》2020年第2期186-189,共4页Clinical Medicine of China

摘　　要：晚期非小细胞肺癌是当今世界难治的恶性肿瘤之一。目前,化疗是治疗非小细胞肺癌最常见的手段。然而,传统化疗在杀伤肿瘤细胞的同时也会对正常细胞产生杀伤作用。为了解决这一问题,节拍化疗应运而生,其通过一种连续高频率、低剂量的给药方式,以抑制肿瘤血管的生成并抑制肿瘤生长。节拍化疗可以有效控制晚期非小细胞肺癌患者的疾病进展,延缓患者寿命,改善其生活质量。因此,节拍化疗已经成为治疗晚期非小细胞肺癌有效的治疗方法。Advanced non-small cell lung cancer is one of the most difficult malignant tumors in the world.At present,chemotherapy is the most common treatment for NSCLC.However,traditional chemotherapy can kill tumor cells as well as normal cells.In order to solve this problem,metronomic chemotherapy came into being.It can inhibit tumor angiogenesis and tumor growth through a continuous high-frequency,low-dose administration.Metronomic chemotherapy can effectively control the disease progression of advanced NSCLC patients,delay their life span and improve their quality of life.Therefore,metronomic chemotherapy has become an effective treatment for advanced non-small cell lung cancer.

关 键 词：肺癌 节拍化疗 肿瘤 

分 类 号：R734[医药卫生—肿瘤]